![](https://ml.globenewswire.com/media/e2b3e18c-12ea-4fff-90de-ec6eec7be823/small/logo-png.png)
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 – IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“ …